FindTrial
Sign In

To assess relationship between CA125 and dysmenorrhea and menorrhagia in adenomyosis

The value of CA 125 as a biomarker for assessing the severity of Dysmenorrhea and Menorrhagia in Adenomyosis - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067675
Enrollment
105
Registered
2024-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Dr Sutanka Sujaini
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Females belonging to menstrual age group who understand and give informed consent - Diagnosed with Adenomyosis based on USG findings using MUSAâ??s criteria and having symptoms of dysmenorrhea or menorrhagia - Patients with above symptoms who have been given CA125 test.

Exclusion criteria

Exclusion criteria: - Patient who have not consented for the study. - Patients diagnosed with gynecological malignancies

Design outcomes

Primary

MeasureTime frame
VAS Score Pictorial Blood Loss Assessment Chart (PBAC) The association between CA 125 and Menorrhagia or Dysmenorrhea will be analysed and the impact of focal vs diffuse adenomyosis will be assessed. Timepoint: Baseline, 8 weeks—

Secondary

MeasureTime frame
To study the factors affecting CA125. To study diffuse vs focal type of adenomyosis and its relation with CA125 levels The association between CA 125 and Menorrhagia or Dysmenorrhea will be analysed and the impact of focal vs diffuse adenomyosis will be assessed. Timepoint: Over 2 years duration—

Countries

India

Contacts

Public ContactDr Sutanka Sujaini

Kasturba Hospital, Manipal

drram.nambiar@manipal.edu919845082923

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026